Iodine-125 brachytherapy has been applied to brain tumours since 1979. Even though the physical and biological characteristics make these implants particularly attractive for minimal invasive treatment, the place for stereotactic brachytherapy is still poorly defined.An extensive review of the literature has been performed, especially concerning indications, results and complications. Iodine-125 seeds have been implanted in astrocytomas I-III, glioblastomas, metastases and several other tumour entities. Outcome data given in the literature are summarized. Complications are rare in carefully selected patients.All in all, for highly selected patients with newly diagnosed or recurrent primary or metastatic tumours, this method provides encouraging survival rates with relatively low complication rates and a good quality of life.
In comparison to age-matched men, young women are at increased risk to suffer from venous thromboembolism (VTE). Some risk factors of inherited and acquired thrombophilia are known, but approximately 30% of the overall risk remains unexplained. Recently, a role for microparticles (MP) in coagulation has been suggested. We investigated, if gender- and menstrual cycle-specific differences in circulating MP exist. Platelet- and endothelial cell-derived microparticles (PMP, EMP) and subpopulations thereof were evaluated flow-cytometrically in healthy women (n = 27) in different phases of their menstrual cycles (follicular phase: n = 14, luteal phase: n = 13) and in healthy men (n = 18). Additionally, D-dimer levels were determined. Compared to men, women had elevated numbers of annexin V-binding MP (p = 0.007), PMP (CD61; p = 0.013), P-selectin-exposing PMP (p = 0.002) and E-selectin-exposing EMP (p = 0.009). During the luteal phase, women had strongly elevated concentrations of MP, PMP, P-selectin- and CD63-exposing PMP as well as E-selectin-exposing EMP (p = 0.001, p < 0.001, p = 0.004, p = 0.003, and p < 0.001, respectively), and the ratio of P-selectin-exposing PMP/platelet increased more than three-fold as compared to men (p = 0.01). When different phases of the menstrual cycle were analysed, MP (annexin V; p = 0.025), PMP (CD61: p < 0.001; CD63: p = 0.015) and E-Selectin-positive EMP (p = 0.006) were all increased in the luteal phase. Although D-dimer concentrations in women were increased compared to men (p = 0 = 0.006), no menstrual cycle-specific differences were observed. In summary, circulating MP and subpopulations thereof are increased in women when compared to men, and this increase seems to be modulated by the menstrual cycle. Therefore, circulating MP may be an additional risk factor contributing to the hitherto unexplained procoagulatory state of young women.
Higher concentrations of microparticles derived from (activated) platelets/megacaryocytes were present in postmenopausal women taking hormonal replacement therapy. This finding indicates a procoagulant state in these women and might play a role in the development of venous side effects. In contrast, levels of endothelial cell-derived microparticles did not differ.
Background: Climacteric increases the risk of thrombotic events by alteration of plasmatic coagulation. Up to now, less is known about changes in platelet- (PMP) and endothelial cell-derived microparticles (EMP). Methods: In this prospective study, plasma levels of microparticles (MP) were compared in 21 premenopausal and 19 postmenopausal women. Results: No altered numbers of total MP or EMP were measured within the study groups. However, the plasma values of CD61-exposing MP from platelets/megakaryocytes were higher in premenopausal women (5,364 × 106/l, range 4,384–17,167) as compared to postmenopausal women (3,808 × 106/l, range 2,009–8,850; p = 0.020). This differentiation was also significant for the subgroup of premenopausal women without hormonal contraceptives (5,364 × 106/l, range 4,223–15,916; p = 0.047; n = 15). Furthermore, in premenopausal women, higher plasma levels of PMP exposing CD62P were also present as compared to postmenopausal women (288 × 106/l, range 139–462, vs. 121 × 106/l, range 74–284; p = 0.024). This difference was also true for CD63+ PMP levels (281 × 106/l, range 182–551, vs. 137 × 106/l, range 64–432; p = 0.015). Conclusion: Climacteric lowers the level of PMP but has no impact on the number of EMP in women. These data suggest that PMP and EMP do not play a significant role in enhancing the risk of thrombotic events in healthy, postmenopausal women.
BackgroundConventional external beam radiotherapy is a standard procedure for treatment of spinal metastases. In case of progression spinal cord tolerance limits further radiotherapy in pre-irradiated areas. Spinal stereotactic radiotherapy is a non-invasive option to re-treat pre-irradiated patients. Nevertheless, spinal radiosurgery results in relevant dose deposition within the myelon with potential toxicity. Aim of the study was to retrospectively analyse the efficacy and feasibility for salvage radiosurgery of spinal metastases.MethodsDuring a period of 4 years (2005-2009) 70 lesions in 54 patients were treated in 60 radiosurgery sessions and retrospectively analysed. Clinical (pain, sensory and motor deficit) and radiological (CT/MRI) follow-up data were collected prospectively after radiosurgery. Pain - as main symptom - was classified by the Visual Analogue Scale (VAS) score. Every patient received single session radiosurgery after having been treated first-line with conventionally fractionated radiotherapy. Kaplan-Meier method and life tables were used to analyse freedom from local failure and overall survival.ResultsAt a median follow-up of 14.5 months the actuarial rates of freedom from local failure at 6/12/18 months were 93%, 88% and 85%, respectively. The median radiosurgery dose was 1 × 18 Gy (range 10-28 Gy) to the median 70% isodose. The VAS score of patients with pain (median 6) dropped significantly (median 4, p = 0.002). In 6 out of 7 patients worse sensory or motor deficit after SRS was caused by local or distant failures (diagnosed by CT/MRI). One patient with metastatic renal cell carcinoma developed a progressive complete paraparesis one year after the last treatment at lumbar level L3. Due to multiple surgery and radiosurgery treatments at the lumbar region and further local progression, the exact reason remained unclear. Apart from that, no CTC grade III or higher toxicity has been observed.ConclusionsBy applying spinal radiosurgery relevant radiation doses can be limited to small parts of the myelon. This prevents myelopathic side effects and makes it an effective and safe treatment option for well-suited patients. Especially for previously irradiated patients with local failure or pain salvage SRS represents a valuable treatment option with high local control rates, low toxicity and significant pain reduction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.